The JAK2/FLT3 inhibitor pacritinib (15) demonstrated synergy with the histone deacetylase (HDAC) inhibitor pracinostat (26) in mouse AML models (Novotny-Diermayr et al., 2012). The gene discussed is HDAC9; the disease is acute myeloid leukemia.